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Abstract Directly observed standardized short-course che-
motherapy (DOTS) regimes are an effective treatment for
drug susceptible tuberculosis disease. Surprisingly, DOTS
has been reported to reduce the transmission of multi-drug
resistant tuberculosis, and standardized short-course che-
motherapy regimens with first-line agents have been found
to be adequate treatments for some patients with drug
resistant tuberculosis, including multi-drug resistance.
These paradoxical observations and the apparent heteroge-
neity in treatment outcome of multi-drug resistant tuber-
culosis when using standard regimens may be due in part to
limitations of in vitro drug susceptibility testing based on
unique but mistakenly used techniques in diagnostic
mycobacteriology. Experimental data and mathematical
models indicate that the fitness cost conferred by a
resistance determinant is the single most important param-
eter which determines the spread of drug resistance.
Chromosomal alterations that result in resistance to first-
line antituberculosis agents, e.g. isoniazid, rifampicin,
streptomycin, may or may not be associated with a fitness
cost. Based on work in experimental models and from
observations in clinical drug resistant isolates a picture
emerges in which, among the various resistance mutations
that appear with similar rates, those associated with the
least fitness cost are selected in the population.
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Tuberculosis (TB) has been and still is one of the most
common infectious causes of death on earth [16]. Treatment
of tuberculosis disease faces three problems: (1) interrup-
tion of further transmission, (2) curing the acute disease,
and (3) preventing relapse (most relapses occur within 6–
12 months after completion of therapy). A number of
landmark historical clinical studies [e.g. 9, 30, for review
32] have defined the principles which form the basis for
successful drug treatment of tuberculosis disease and have
resulted in the current concept of standard short-course
chemotherapy (SSC). Today, the most commonly used
standard chemotherapy of tuberculosis is a combination
therapy consisting of a total of six months of drug
treatment. Combination therapy is necessary for successful
treatment of the acute infection and for prohibiting
resistance to emerge, while a minimum treatment length
of 6 months is required to prevent relapse of the disease.
The ongoing TB pandemic is a serious threat, in particular
for the developing countries, which carry most of its
burden. Worldwide, the current situation is characterized
by increasing numbers of drug-susceptible tuberculosis
disease and by emerging drug resistance [46, 47, 50, 54].
Much attention has focused on the burden of multi-drug
resistant (MDR) TB [18, 47, 55]. At present, MDR-TB
continues to be a significant problem, not only in the
developing countries, but also in the Baltic region, parts of
the former Soviet Union, and other areas of the world.
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Drug resistance and susceptibility testing
in the laboratory
Plasmid-mediated mechanisms of resistance are absent in
tuberculous mycobacteria, as acquired drug resistance is
exclusively due to chromosomal alterations such as
mutations or deletions. These chromosomal alterations
affect either the drug target itself or bacterial enzymes
activating the prodrug. During the past 15 years, significant
knowledge has been gained concerning the mechanisms of
mycobacterial drug resistance at the molecular level [for
review see 36]. Isoniazid is a prodrug that requires activa-
tion by the catalase-peroxidase enzyme encoded by the
katG gene. Resistance to isoniazid is mainly due to
alterations within katG. In contrast, resistance to rifampicin
or streptomycin is due to mutational alterations in genes
encoding the drug target such as rpoB, rpsL, or rrs.
MDR-TB by definition implies resistance to at least
isoniazid and rifampicin, the two cornerstone drugs of
standard short-course therapy. A treatment based on isoni-
azid and rifampicin can not be expected to cure or
substantially improve tuberculosis in patients infected with
MDR-TB, nor should ineffective treatment reduce the
transmission of multi-drug resistant tuberculosis. However,
implementation of the DOTS program should reduce
acquisition of drug resistance generated by erratic, unsuper-
vised therapy and by an unreliable drug supply. When
applied to populations with high rates of existing drug
resistance, DOTS has been found to further amplify
resistance [33]. In epidemiological terms, treating all
patients with standard short-course therapy alone will
suppress drug-susceptible strains and select for transmission
of drug-resistant strains at a population level. Surprisingly,
standard short-course therapy has been found to be an
effective cure for 30–50% of patients with MDR-TB [19],
and implementation of DOTS has been reported to reduce
transmission of MDR-TB [17].
How to explain these counterintuitive observations?
Meta-analyses of the impact of drug resistance on treatment
outcome and transmission are complicated by the use of
different methods and drug concentrations for phenotypic
drug susceptibility testing in various countries. For the first-
line antituberculosis drugs, there is a correlation between
the drug susceptibility testing result in-vitro and the clinical
usefulness of the drug. Based on historical data gathered in
the 1960s [11, 12], there has been a generally accepted
consensus on how laboratory testing of drug susceptibility
of Mycobacterium tuberculosis should be performed [23,
42]. The definition of resistance in the mycobacteriology
laboratory dates back to 1962: “Resistance is defined as a
decrease in sensitivity of sufficient degree to be reasonably
certain that the strain concerned is different from a sample
of wild strains of human type that have never come into
contact with the drug”. This definition is an epidemiolog-
ical one. Already in 1969 the prognostic significance of in
vitro determined drug resistance had been found to be
limited. “There is evidence that the presence of resistance to
a single drug has little or no effect on the outcome of
treatment with the three drugs isoniazid, streptomycin, and
para-amino salicylic acid. Furthermore, even in the pres-
ence of primary resistance to two first-line drugs, a
bacteriological response is not infrequently obtained with
the three drug regimen” [11].
In the diagnostic laboratory, a single drug concentration,
termed “critical concentration”, is primarily used for drug
susceptibility testing and to categorize a clinical isolate of
M. tuberculosis as susceptible or resistant [23]. This
“critical concentration”, however, bears little relationship
to the drug concentrations which are present in vivo in the
patient (see Table 1), e.g. the serum concentrations for
isoniazid and streptomycin are 10- to 20-fold higher
compared to the “critical concentration”. This contrasts
with common procedures established in antibiotic therapy
of infectious diseases which take pharmacokinetic proper-
ties into account and where the relationship between
phenotypic resistance in vitro and drug concentration in
vivo is addressed by the definition of breakpoints. Thus, the
resistance phenotype determined in vitro is related to the
drug levels which are present in vivo. What is needed in
diagnostic mycobacteriology are standardized measures of
quantitative drug susceptibility testing. For example, iso-
lates categorized as resistant according to the “critical
concentration”, should be subjected to determination of
minimal inhibitory concentrations.
For streptomycin and isoniazid, a significant fraction of
clinical TB isolates categorized as resistant in the diagnostic
laboratory exhibits only a low-level resistant phenotype
[31, 51]. A successful treatment outcome despite a resistant
phenotype—as determined by routine drug susceptibility
testing—most likely reflects limitations of the procedures
used to determine drug susceptibility and indicates that
Table 1 Mycobacterial drug susceptibility testing—the critical con-
centration
Antimicrobial
agent
MIC [mg/l] of
susceptible M.
tuberculosis
Concentration
[mg/l] in
serum
Concentration
[mg/l] used
for testing
Low High
Isoniazid 0.05–0.2 7 0.1 0.4
Rifampicin 0.5 10 2 –
Pyrazinamid 20 45 100 –
Ethambutol 1–5 2–5 2.5 7.5
Streptomycin 1 25–50 2 6
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low-level drug resistance may not correspond to clinical
resistance [6, 15, 37]. The NCCLS subcommittee has
incorporated parts of these considerations in its guidelines.
“In the case of isoniazid, if an isolate is resistant to the
critical concentration of 0.1 μg/ml but susceptible to the
higher concentration of 0.4 μg/ml, the following comment
should be given—the test results indicate low-level resis-
tance to isoniazid: some evidence suggests that patients
infected with corresponding strains may benefit from
continuing therapy with isoniazid” [42]. According to
results from systematic quantitative drug susceptibility
testings at the National Center for Mycobacteria (IMM,
University of Zurich), more than one-third of clinical TB
strains categorized as resistant to isoniazid in Switzerland
exhibit a low-level resistant phenotype with MIC values
less than 1.0 mg/l. In contrast, rifampicin resistance,
predominantly corresponds to a high-level drug resistant
phenotype with MIC values >50 mg/l (our own unpub-
lished data). These data lead to the hypothesis that some
strains categorized by in vitro drug susceptibility testing as
MDR-TB strains may not correspond to clinical multi-drug
resistance, in vivo. Treatment of corresponding infections
with a standard short-course regimen is likely to cure the
acute disease, thus providing an adequate explanation for
the seemingly paradoxical observations that DOTS repre-
sents not only an effective treatment for a significant
fraction of MDR-TB disease, but also reduces transmission
of primary MDR-TB. It remains unclear, however, whether
SSC based regimens will effectively prohibit relapse under
these conditions.
The consequences of erratic drug susceptibility testing
are particular severe in terms of treatment options for
apparent MDR or XDR tuberculosis. Isoniazid resistance
reported by the diagnostic laboratory may lead to the use of
second or even third-line antibiotics—compounds which
are compromised by severe toxicity and which almost
certainly have inferior activity than isoniazid against low-
level INH resistant strains. The thioamide drugs, ethion-
amide (ETH) and prothionamide (PTH), are reasonable
treatment options for MDR tuberculosis. Isoniazid and the
thioamide drugs share InhA as the primary target of action
[36, 52]. In contrast to isoniazid, the thioamides do not
require activation by KatG. Thus, strains with high-level
isoniazid resistance due to mutational KatG alterations
typically retain thioamide susceptibility. Newly introduced
molecular diagnostic tests (e.g. the GenoType MTBDR
assay) offer rapid determination of genotypic resistance, as
they allow for the direct detection of the most frequent and
relevant rpoB, katG and inhA resistance mutations in
smear-positive specimens [40]. These tests may assist in
therapeutic decisions in treatment of drug-resistant tuber-
culosis, e.g. whether to use isoniazid or the alternative
thioamide drugs.
Compared to isoniazid, rifampicin, and streptomycin,
drug susceptibility testing for ethambutol is particularly
problematic [28]. A number of reasons may account for
this, e.g. the bacteriostatic nature of ethambutol and
reduced activity of the drug in culture medium. Most
important, however, is the small difference between the
drug concentration used for in vitro drug susceptibility
testing and the natural drug susceptibility of wild-type
isolates of M. tuberculosis (see Table 1). Thus, minute
changes in drug susceptibility will have a major impact on
the interpretation of the in vitro test result, with only a
narrow range between MICs of susceptible and MICs of
resistant isolates of M. tuberculosis. Despite identification
of the emb gene cluster, proposed to encode for a
mycobacterial arabinosyl transferase, as a target for
ethambutol [2], the role of the emb operon in resistance is
unclear [43]. In particular, the association of embB codon
306 mutation with ethambutol resistance in M. tuberculosis
remains enigmatic [21, 24, 34]. This is not the least due to
the lack of clear-cut gene replacement experiments in M.
tuberculosis using the codon 306 mutant embB allele.
Drug resistance and fitness
A common perception in drug resistance implies that drug
resistance has a cost: a drug resistance determinant provides
an advantage in the presence of the drug, but in the absence
of the drug the resistance determinant is associated with a
fitness burden [5, for review 1]. In mathematical models,
the fitness cost of drug resistance is the primary
parameter that determines both the frequency of resis-
tance at any given level of antibiotic use and the rate at
which that frequency will change with changes in
antibiotic use patterns. Experimentally, in the laboratory,
it has been demonstrated that compensatory mutations
may occur which counteract the fitness burden associated
with a primary resistance determinant. These compensa-
tory mutations have been suggested to maintain the
spread of resistance even in the absence of antibiotics
[1]. In case a fitness lowering chromosomal alteration
occurs, two possibilities thus exist: (1) the mutant carrying
the chromosomal alteration becomes extinct, or (2) the
chromosomal alteration is fixed in the population by means
of a compensatory evolution.
A different and particularly instructive picture emerged
when studying the mechanisms of streptomycin resistance
in M. tuberculosis [7]. The results of these studies question
the dogma of a resistance-associated fitness cost. These
investigations were the first to combine data on the
frequency of molecular resistance determinants in clinical
isolates in vivo with in vitro experimental data on the
genetics and costs associated with a resistance determinant.
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The procedure involved three steps: (1) to determine the
frequency of resistance mutations in drug resistant M.
tuberculosis strains isolated from patients versus the
frequency in in vitro selected drug resistant mutants, (2)
to introduce resistance determinants by means of genetic
techniques into a suitable model to obtain isogenic mutants,
and (3) to experimentally determine the fitness cost of a
resistant determinant in an in vitro competition growth
assay. In vitro, a variety of mutations in either ribosomal
protein S12 or the small subunit rRNA result in resistance
to streptomycin. However, in vivo a strict correlation was
found between the frequency of a given resistance mutation
in clinical isolates and its fitness cost as determined in vitro.
The no-cost Lys → Arg alteration at position 42 of rpsL is
by far the most frequent streptomycin resistance mutation in
clinical isolates (see Table 2). An important control was to
determine the stochastic probability of the different re-
sistance mutation in vitro: no such correlation is found
here [8, 38]. Thus, while the stochastic probabilities of the
different resistance mutations may be similar, there is a
significant selection in vivo for those resistance mutations
which carry no fitness cost.
Crystallographic data on ribosome-drug complexes
have helped to understand the fitness cost associated with
the various streptomycin resistance mutations [13]. Most
of the streptomycin resistance mutations will affect the
fidelity of translation by leading to ribosomal hyper-
accuracy. Among the different rpsL mutations conferring
resistance to streptomycin, e.g. Lys 42→Arg, Thr or Asn,
the replacement of lysine by arginine at aa position 42 is the
only mutation known that confers resistance to streptomy-
cin without affecting the fidelity of translation [26].
Mutation of lysine to arginine would disrupt hydrogen-
bonding contacts to the OH groups of streptomycin (see
Fig. 1) and thereby reduce the affinity of the ribosome for
streptomycin, leading to resistance. Compared to the
streptomycin resistance mutations RpsL aa 42 Lys→Thr
or Asn, however, the Lys→Arg alteration does not affect
intra-ribosomal contacts of aa 42 to small subunit RNA
nucleotides and thus translation remains normal.
These recent experimental results addressing the mo-
lecular mechanisms of resistance and fitness cost are cor-
roborated by epidemiological observations from some
40 years ago [10]. In his investigations, Canetti studied
primary versus acquired drug resistance in M. tuberculosis.
Primary resistance is defined as infection with a resistant
strain, here a resistant strain is transmitted from patient to
patient. Acquired resistance is defined as resistance devel-
oping in a patient following infection with a drug susceptible
strain. “Primary resistance is not a mere replication of
acquired resistance. Other factors, such as altered virulence
of the resistant strains, or instability inherent to certain types
of resistance, may also be at work in producing the
difference. If some of the strains with acquired resistance
are incapable (through insufficient virulence) of producing
new cases of tuberculosis .... the relative frequency of
resistance must necessarily be lower in primary than in
acquired resistance” [10].
Canetti categorized streptomycin resistance into low-
level (≥4 μg/ml), intermediate-level (≥10 μg/ml) and high-
level (≥100 μg/ml) drug resistance (see Table 3). At this
gross level, there was no significant difference between
Table 2 Frequency of genotypic alterations in clinical M. tuberculosis
isolates resistant to streptomycina
Mutations Frequency in
clinical isolates
Mean relative
fitness
MIC mg/L
rpsL 42 Arg 88% 0.98 >1,000
rrs 523 C 6% 0.94 125
rrs 522 T 3% 0.91 250
Rrs 526 T 2% 0.90 125
rpsL 42 Thr <1% 0.86 >1,000
rpsL 42 Asn <1% 0.85 >1,000
a Resistance mutations in rpsL aa position 88 and in rrs positions 501,
912, and 913 are not included; these mutations account for
approximately 10% of clinical streptomycin resistant isolates
Fig. 1 Chemical structure of streptomycin, showing interaction of the
various groups with specific residues of the Thermus thermophilus
small ribosomal subunit; nucleotides correspond to 16S rRNA, Lys 45
(S12) corresponds to ribosomal protein RpsL aa position 42. Figure
taken from Ref. 13 with permission of the publisher
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primary and acquired drug resistance with respect to the
relative proportions of the different streptomycin resistance
levels. In other words, within streptomycin resistant
mutants high-level drug resistance mutations must exist
which did not impede transmission. For rifampicin, the
situation is similar. Different mutations in rpoB result in
drug resistance [4, 20, 22, 29]. As with streptomycin, a
significant correlation exists between the frequency of a
particular mutation in clinical isolates and the fitness cost
associated with the mutation (see Table 4).
For isoniazid, the situation is different. Compared to
acquired resistance, the high-level resistance phenotype is
significantly underrepresented in primary resistance (11%
versus 53%, see Table 5). Apparently, high-level isoniazid
resistance is associated with a significant fitness burden
which impedes transmission. Multiple chromosomal alter-
ations in katG may result in resistance to isoniazid. It was
demonstrated some 50 years ago that high-level resistance
to isoniazid—as conferred by deletion of katG, i.e.
complete loss of katalase-peroxidase activity—is associated
with a significant fitness cost [14]. More recently, it was
shown that complete loss of KatG activity in clinical
isoniazid resistant strains is associated with a secondary
mutation resulting in over-expression of the alkyl-hydro-
peroxide-reductase AhpC [39]. It was hypothesized that in
strains with isoniazid resistance due to deletion of katG,
compensatory mutations in ahpC will develop over time,
ultimately facilitating transmission and spread of resistant
microorganisms. The most frequent isoniazid resistance
mutation found in clinical strains, however, is not a
nonsense mutation, but a serine to threonine replacement
at aa position 315 of KatG [48, 49]. This particular
mutation confers an intermediate level of resistance and is
not associated with a fitness cost [35]. The 315 Ser→Thr
mutation is found in approximately 60% of clinical strains
with isoniazid resistance. In the absence of KatG/isoniazid
crystal complexes, modelling and computational studies
have been used to understand drug–target interaction [3].
These and other studies suggest [25] that a 315 Ser→ Thr
mutation in the KatG catalase–peroxidase would alter the
binding site for isoniazid but retain the active site properties
for proper catalytic function.
Available evidence suggests that within a spectrum of
possible mutational resistance alterations each being asso-
ciated with a distinct fitness cost, a selection for those
resistance mutations with the least resistance-associated
cost seems to exist in vivo [4, 8, 29, 35, 38, 49]. This
selection is best explained by fluctuating environments, i.e.
expansion of mutants experiencing a low fitness cost in the
absence of antibiotics during periods in which selection for
antibiotic resistance is removed. The rare finding of high
cost resistance mutations in clinical isolates can be explained
by the stochastic probability of a resistance mutation in a size
limited bacterial population and by bottleneck phenomena
which take place in transmission. It is under such conditions
that compensatory mutations which ameliorate the cost of
resistance are likely to occur [38].
A priori, there is no need for compensatory evolution in
maintaining persistence and further spread of drug resis-
tance, as resistance mutations exist which carry little or no
fitness cost at all. As long as for a given drug different
resistance mutations exist with only one of these being a
no-cost resistance mutation, the stochastic probability of
selection for this particular mutation in a given population
is much higher than the probability of two mutations
occurring either simultaneously or successively with one
compensating for disadvantages conferred by the other. The
frequent presence of and selection for drug resistance
mutations which carry no or only a low fitness cost, also
indicates that drug persistence per se can not be expected to
restrict transmission of tuberculosis disease.
Table 3 Primary resistance and acquired resistance to streptomycin
Total cases Concentration of streptomycin [μg/ml]
≥4 ≥10 ≥100
n % n % n % n %
Primary resistance 163 100 94 58 34 21 35 21
Acquired resistance 426 100 267 63 102 24 57 12
Table 4 Frequency of rpoB mutations in clinical M. tuberculosis
isolates resistant to rifampicina
RpoB mutation Frequency in
clinical isolates
Mean relative
fitness
MIC mg/l
S 531 L 54% 0.93 >32
H 526 Y 11% 0.82 >32
H 526 D 7% 0.78 >32
S 531 W 4% 0.79 >32
H 526 R 3% 0.56 >32
S 522 L 1% 0.54 16–32
a Data tabulated from [4, 20, 22, 29]
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Limitations of the DOTS strategy
In 1994, the WHO declared tuberculosis a global emergen-
cy and introduced the DOTS strategy for global tuberculo-
sis control. However, the plan has produced variable
success and despite intensified efforts to diagnose and treat
tuberculosis, the rates continue to climb in some regions.
Although various experts have argued that the failure of the
DOTS strategy to control tuberculosis resulted from failed
implementation, poor public health infrastructure, poverty,
and the like, recent reports indicate that the problem with
the DOTS strategy may be a more principal one [45, 53].
For example, tuberculosis rates were found to increase de-
spite implementation of DOTS [27]. The DOTS strategy is
built around five activities: (1) case detection by sputum
smear microscopy among symptomatic patients self-reporting
to health services, (2) directly observed therapy using stan-
dard short-course regimens, (3) regular supply of medication,
(4) governmental commitment to sustained tuberculosis
control by providing resources and infrastructural capacity,
and (5) a standardized recording and reporting system that
allows assessment of individual treatment results and of the
tuberculosis control program overall.
The reproductive rate of an epidemic is characterized by
three determinants: (1) the duration of infectiousness of an
infected patient, (2) the number of contacts between an in-
fectious patient and susceptible contacts, and (3) the prob-
ability of the infected to become infectious. As a treatment
program, DOTS in part targets the duration of infectious-
ness. However, DOTS does not address the number of
contacts between an infectious patient and susceptible
contacts before diagnosis on the basis of passive case-
finding [44], nor does it address the probability of the
infected to become infectious. It has been estimated that
approximately one tenth of those infected develop active
disease and half of those with active disease become
themselves infectious [41]. Thus, it would be necessary
for one tuberculosis case to infect approximately twenty
susceptible contacts in order to produce another infectious
case and to maintain the same level of infection in the
population. Any measure which decreases this number will
result in a decline of tuberculosis rates. Two simple
calculations may serve to illustrate the limitations of a
mere treatment program based on passive case finding.
First, a patient, prior to detection on the basis of passive
case finding, infects more than 20 susceptible contacts
before transmission is interrupted by treatment. This is a
scenario which is quite conceivable under the living
conditions present in many of the world’s underdeveloped
areas. Second, rather than 10%, a significantly larger
fraction of the infected develops active disease, due to
either inherent genetic (disease susceptibility and genetic
polymorphisms), societal (poverty and starvation), or
environmental reasons, e.g. coinfection with HIV. The
latter is particularly worrisome due to the widespread
nature of the AIDS epidemic and its association with a
high risk of developing progressive primary tuberculosis.
Under these circumstances, the DOTS program will have
significant shortcomings in the global control of TB.
More data are needed to estimate our case finding ability
in various settings. Available data indicate that in high
burden environments it may be quite low, e.g. in South
Africa. In that case, no strategy will reduce incidence,
unless case finding ability is enhanced [45]. The current
WHO recommendations form an excellent base for tuber-
culosis control, but may need to be complemented by a
strategy which reflects the biology of the disease by
considering determinants which influence the reproductive
rate of an epidemic. The DOTS program as a treatment
program is ideally combined with a component which
actively targets transmission, designed to interrupt the
spread of M. tuberculosis in the community. Such a
component could be the implementation of contact tracing
and active case finding. Can we afford to do it, or rather,
can we afford to ignore it?
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Table 5 Primary resistance and acquired resistance to isoniazid
Total cases Concentration of isoniazid [μg/ml]
≥0.2 ≥1 ≥10
n % n % n % n %
Primary resistance 98 100 49 50 38 39 11 11
Acquired resistance 443 100 114 26 95 21 234 53
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